Latest Headlines from Cafepharma

J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B

BioPharma Dive — Mon, 08 Jun 2026 12:04:08 -0400

Johnson & Johnson will acquire biotechnology startup Firefly Bio in a deal worth $1 billion in cash, a move that hands the pharmaceutical giant access to technology for making new types of therapies called “degrader-antibody conjugates,” the companies said Monday.

ADA: Lilly sets ‘new record in Weight Loss Olympics’ with next-gen asset

BioSpace — Mon, 08 Jun 2026 12:00:05 -0400

Over two years of treatment, Eli Lilly’s triple-G drug cut body weight by more than 30% in certain patients with obesity, cementing the pharma’s position as the frontrunner in the metabolic space.

Sanofi and Owkin partner to develop next-generation biopharma AI agents

Pharmaceutical Technology — Mon, 08 Jun 2026 11:40:18 -0400

Sanofi has entered a multi-year agreement with France-based agentic AI company Owkin to co-develop next-generation AI-driven biopharma agents.

The partnership includes a five-year licence for Owkin’s K Pro, an AI platform designed to augment drug discovery and development.

ADA: Metsera asset data support Pfizer’s ‘entry point’ into obesity market

BioSpace — Mon, 08 Jun 2026 11:32:36 -0400

Much work needs to be done for Pfizer to be able to catch up to the weight-loss frontrunners, according to Guggenheim Partners, but new data from Metsera’s lead asset could set the pharma apart from competitors with a monthly injection.

ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction

BioSpace — Mon, 08 Jun 2026 11:30:16 -0400

While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.

Combination of Pancreatic Cancer Drugs from Tango and Revolution Yields High Response in Early Clinical Trial

The Bio Intel — Mon, 08 Jun 2026 11:22:54 -0400

A combination approach involving investigational drugs from Tango Therapeutics and Revolution Medicines has shown a high response rate in treating pancreatic cancer in an early-stage clinical study. The findings may signal promising new options for patients in need of better therapies.

Boston Scientific to build Indiana distribution center

Medtech Dive — Mon, 08 Jun 2026 11:12:22 -0400

Boston Scientific is investing approximately $138 million to build a 500,000-square-foot distribution facility in Plainfield, Indiana.
Indiana Gov. Mike Braun, who announced the project last week, said Boston Scientific will break ground on the facility this year and ultimately create up to 300 jobs.

Medtronic seeks clearance for Hugo surgical robot in more indications

Medtech Dive — Mon, 08 Jun 2026 11:09:58 -0400

Medtronic said last Wednesday it has filed for 510(k) clearance to expand the use of its Hugo surgical robot to general and gynecological indications.
The Food and Drug Administration cleared the device in urologic procedures late last year. Expanding the label would position Medtronic to compete with Intuitive Surgical in more indications.

Incyte gobbles up Star's Vega hematology unit in $2bn deal

Pharmaphorum — Mon, 08 Jun 2026 11:06:15 -0400

Incyte has agreed to buy Star Therapeutics subsidiary Vega Therapeutics for $1.25 billion upfront, adding a late-stage drug candidate for bleeding disorders.

Roche doubles down on BTK with $2.3bn Nurix deal

Pharmaphorum — Mon, 08 Jun 2026 11:01:59 -0400

Roche is preparing to file one BTK-targeting drug for approval, and has just added another with potential across oncology, immunology, and neurology via a deal with Nurix Therapeutics.

3 potential takeover targets in obesity

Pharma Voice — Mon, 08 Jun 2026 10:54:11 -0400

In particular, companies are eyeing next-generation treatments that build on the slimming power of first-generation GLP-1s with fewer side effects and more patient-friendly dosing.

But the scarcity of late-stage assets is positioning a handful of biotechs as potentially attractive acquisition targets, including the three companies below.

Lilly and Novo face off at ADA 2026 as others seek to compete in obesity

BioSpace — Fri, 05 Jun 2026 11:57:41 -0400

The American Diabetes Association’s annual congress will feature a superstar lineup, including weight loss giants Eli Lilly and Novo Nordisk. But several scrappy biotechs will also present obesity candidates with the potential to match—if not outperform—their deep-pocketed competitors.

Roche chairman likens US tariff policy to 'blackmail'

Economic Times — Fri, 05 Jun 2026 11:55:46 -0400

"If someone points a gun at you and ⁠says 'if you don't sign, there'll be 200% tariffs tomorrow', I wouldn't necessarily describe that as a deal," Schwan said in an interview at an event in the Swiss city of Interlaken, broadcast on Swiss television.

MiniMed expands Abbott partnership to add dual glucose-ketone sensor

Medtech Dive — Fri, 05 Jun 2026 11:52:24 -0400

In its first earnings call, the diabetes tech firm said it was transforming its product portfolio, with plans for a patch pump and an algorithm that doesn’t require meal announcements.

Innovent eyes third-line nod for gastric cancer ADC on Phase III PFS hit

Clinical Trials Arena — Fri, 05 Jun 2026 11:50:23 -0400

Takeda’s $11.4bn bet on assets from Chinese biotech, Innovent Biologics, is showing early signs of paying off, as the latter is seeking the regulatory go-ahead for its gastric cancer asset, arcotatug tavatecan, on home turf following a Phase III win.

Lundbeck’s bocunebart meets primary endpoint in Phase IIb migraine trial

Clinical Trial Vanguard — Fri, 05 Jun 2026 11:48:45 -0400

A treatment difference of just 1.38 monthly migraine days sounds modest until you consider who was in the trial: patients who had already failed between one and four preventive therapies, a population for whom even partial relief represents a meaningful clinical advance. That is the number Lundbeck brought to the American Headache Society congress in Orlando this week, reporting that bocunebart — its investigational anti-PACAP monoclonal antibody — met the primary endpoint of the IV arm of the Phase IIb PROCEED trial with a statistically significant separation from placebo (p=0.0178) over 12 weeks.

Biogen’s salanersen gains FDA breakthrough therapy designation for SMA

Pharmaceutical Technology — Fri, 05 Jun 2026 11:44:03 -0400

Biogen has received the breakthrough therapy designation from the US Food and Drug Administration (FDA) for salanersen (BIIB115), an investigational treatment for spinal muscular atrophy (SMA).

Otsuka’s Voyxact preserves kidney function at 12 months

Clinical Trials Arena — Fri, 05 Jun 2026 11:42:29 -0400

Otsuka Pharmaceutical’s Voyxact (sibeprenlimab-szsi) has preserved kidney function for 12 months in patients with primary IgA nephropathy (IgAN) in a Phase III trial.

Novartis reports positive results from Phase III ALIGN trial for IgAN

Clinical Trials Arena — Fri, 05 Jun 2026 11:41:04 -0400

Novartis has announced final results from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slows kidney function decline versus placebo in adults with IgA nephropathy (IgAN).

First human trial backs AI-designed 'universal' vaccine

Pharmaphorum — Fri, 05 Jun 2026 11:35:58 -0400

An AI-designed vaccine against all variants of the coronavirus SARS-CoV-2 – designed using an AI-powered platform developed at University of Cambridge spinout DIOSynVax – has shown promising results in its first clinical trial.

Roche develops Bundibugyo Ebola test in six days

Pharmaphorum — Fri, 05 Jun 2026 11:29:22 -0400

A PCR diagnostic developed by Roche for the Bundibugyo form of Ebola is being offered to health systems at the front lines of the current outbreak in central Africa.

GSK, Takeda and others notch key clinical wins in tough-to-treat diseases

Pharma Voice — Fri, 05 Jun 2026 11:21:06 -0400

Lilly’s success is among a number of recent clinical trial wins in pharma, with some fueling fresh optimism for tough diseases. Revolution Medicines notched a high-profile victory with its RAS(ON) inhibitor, daraxonrasib, which nearly doubled survival in previously treated pancreatic cancer patients with metastatic disease.

While these may be two of the most dramatic success stories, other companies have moved the needle with trial results in psoriasis, hepatitis B and melanoma. Here are three notable hits.

SCOTUS backs generic firm Hikma in skinny label dispute

Pharmaphorum — Fri, 05 Jun 2026 11:18:18 -0400

A closely-watched lawsuit in the US Supreme Court has reached its conclusion, and sets an important precedent in the battle between brand owners and generic drugmakers over 'skinny' labels for medicines.

GLP-1 drugs may have a beneficial effect across many types of cancer

Devdiscourse — Thu, 04 Jun 2026 12:00:39 -0400

More than two dozen studies presented over the past few days at the American Society of Clinical Oncology meeting in Chicago found that patients taking the drugs showed lower risks of developing cancer and ‌disease progression, better survival, and improved responses to some treatments, compared with people who were not taking the GLP-1s. The studies included analyses of clinical records and real-world databases tracking patients taking Novo Nordisk's Wegovy or Ozempic, Eli Lilly's Zepbound or Mounjaro, or older GLP-1 treatments.

Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success

Motley Fool — Thu, 04 Jun 2026 11:56:59 -0400

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are seeing massive demand.
Like all drugs, Mounjaro and Zepbound have time-limited patent protections.
Eli Lilly is openly telling Wall Street that it is using the windfall from Mounjaro and Zepbound to build for the future.

Massachusetts’ life sciences employment dipped last year following 14 years of growth: report

BioSpace — Thu, 04 Jun 2026 11:55:48 -0400

Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting industry employment will increase 9.7% by 2030. It also noted reskilling needs for some roles, including scientists.

Argenx’s Vyvgart shows durability in myositis and Sjögren’s

Clinical Trials Arena — Thu, 04 Jun 2026 11:51:45 -0400

Argenx’s Vyvgart (efgartigimod alfa-fcab) shows lengthy benefit for myositis and Sjögren’s disease, setting up its anticipated Phase III readouts.

The data presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place in London from 3 to 6 June, has shown durability up to a year in myositis and 72 weeks in Sjögren’s disease.

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

Forbes — Thu, 04 Jun 2026 11:49:41 -0400

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes has learned.

J&J’s nipocalimab meets primary endpoint in Phase II JASMINE study

Clinical Trials Arena — Thu, 04 Jun 2026 11:47:16 -0400

Johnson & Johnson (J&J) has reported that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase II JASMINE study by reducing disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE).

Pharma’s 10 most interesting booths at ASCO

Medical Marketing and Media — Thu, 04 Jun 2026 11:41:50 -0400

Pharma companies invested in flashy displays at ASCO 2026, seeking to carve out a space for themselves as the oncology space becomes increasingly competitive.